Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 2 May 2025 |
| Orion Corporation: Managers' transactions - Veli-Matti Mattila | 2 May 2025 |
| Orion Corporation: Managers' transactions - Eija Ronkainen | 2 May 2025 |
| Orion Corporation: Managers' transactions - Maziar Mike Doustdar | 2 May 2025 |
| Orion Corporation: Managers' transactions - Henrik Stenqvist | 2 May 2025 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 2 May 2025 |